2-Hydroxy-3-(3-hydroxy-4-methoxyphenyl)propanoic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 2-Hydroxy-3-(3-hydroxy-4-methoxyphenyl)propanoic acid
• 化学式: C₁₀H₁₂O₅
• 分子量: 212.2
• InChiKey: UIQJPTIJLALAGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  87
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• ROSMARINIC ACID DERIVATIVE OR SALT THEREOF
  申请人：KAO CORPORATION

  公开号：US20210300859A1

  公开（公告）日：2021-09-30

  The present invention provides a compound that inhibits the activity of TRPV4 and is useful for prevention or amelioration of an overactive bladder, an irritable bowel syndrome, etc. The compound is a rosmarinic acid derivative represented by the following formula (I) or a salt thereof:

  本发明提供了一种抑制TRPV4活性的化合物，可用于预防或改善过度活跃的膀胱、肠易激综合征等。该化合物是以下式（I）所代表的迷迭香酸衍生物或其盐：
• TRPV4 ACTIVITY INHIBITOR
  申请人：Kao Corporation

  公开号：EP3865129A1

  公开（公告）日：2021-08-18

  Provided is a compound that inhibits the activity of TRPV4 and is useful for preventing or ameliorating overactive bladder, irritable bowel syndrome, and the like. A TRPV4 activity inhibitor is provided containing a rosmarinic acid derivative selected from the group consisting of the following formulas (Ia) to (Id), or a salt thereof, as an active ingredient.

  本发明提供了一种抑制 TRPV4 活性的化合物，可用于预防或改善膀胱过度活动症、肠易激综合征等。本发明提供了一种 TRPV4 活性抑制剂，其活性成分含有选自下式（Ia）至（Id）组成的组的迷迭香酸衍生物或其盐。
• GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF
  申请人：Kaleido Biosciences, Inc.

  公开号：EP3071235A1

  公开（公告）日：2016-09-28
• GLYCAN COMPOSITIONS AND USES THEREOF
  申请人：Kaleido Biosciences, Inc.

  公开号：EP3334437A1

  公开（公告）日：2018-06-20
• [EN] GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF<br/>[FR] COMPOSITIONS THÉRAPEUTIQUES DE GYLCANE ET PROCÉDÉS ASSOCIÉS
  申请人：KALEIDO BIOSCIENCES INC

  公开号：WO2016122889A1

  公开（公告）日：2016-08-04

  Preparations of glycan therapeutics, pharmaceutical compositions and medical foods thereof, optionally comprising micronutrients, polyphenols, prebiotics, probiotics, or other agents are provided and methods of making same. Also provided are methods of using said gycan therapeutics, e.g. for the modulation of human gastrointestinal microbiota and to treat dysbioses.